Lasers in Medical Science

, Volume 29, Issue 2, pp 589–598 | Cite as

Melasma and laser treatment: an evidenced-based analysis

  • Shlomit Halachmi
  • Merete Haedersdal
  • Moshe Lapidoth
Original Article
First Online:
Received:
Accepted:

Abstract

The use of lasers in the treatment of melasma has been addressed in case reports, but there is no consensus in the literature regarding the safety, efficacy, or durability of laser-based treatments. Furthermore, given the potential risks of laser intervention in hyperpigmented skin, the relative risks and benefit of laser must be compared to more conservative and traditional treatment approaches. English language literature in which the main intervention was a light-based therapy and the target was melasma was analyzed. The study included only prospective, controlled studies which included at least 10 participants, and which presented the data with accepted objective and quantitative study metrics. Seven studies met the inclusion criteria. Two studies reported the response to melanin-targeting lasers and five reported the response to fractional photothermolysis. The response to lasers was not consistent among the reports. Adverse events including hyperpigmentation were reported in several studies. The durability of melasma improvement was limited in all cases where laser was used as monotherapy. In studies that compared laser to topical treatments, laser-based monotherapy failed to show benefit over topical treatments. This analysis suggests that the use of lasers for the treatment of melasma cannot be recommended, due to unpredictable safety and efficacy, time-limited clinical improvement, and no clear benefit over conventional treatments.

Keywords

Melasma Dyschromia Dyspigmentation Chloasma Laser Fractional photothermolysis 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Sheth VM, Pandya AG (2011) Melasma: a comprehensive update: part I. J Am Acad Dermatol 65:689–697PubMedCrossRefGoogle Scholar
  2. 2.
    Sheth VM, Pandya AG (2011) Melasma: a comprehensive update: part II. J Am Acad Dermatol 65:699–71PubMedCrossRefGoogle Scholar
  3. 3.
    Achar A, Rathi SK (2011) Melasma: a clinico-epidemiological study of 312 cases. Indian J Dermatol 56:380–382PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Wiedemann C, Nagele U, Schramm G et al (2009) Inhibitory effects of progestogens on the estrogen stimulation of melanocytes in vitro. Contraception 80:292–298PubMedCrossRefGoogle Scholar
  5. 5.
    Hassan I, Kaur I, Sialy R et al (1998) Hormonal milieu in the maintenance of melasma in fertile women. J Dermatol 25:510–512PubMedGoogle Scholar
  6. 6.
    Resnik SS (1966) Combined or sequential oral contraceptives may cause melasma without total regression. JAMA 197(Suppl 25)Google Scholar
  7. 7.
    Lutfi RJ, Fridmanis M, Misiunas AL et al (1985) Association of melasma with thyroid autoimmunity and other thyroidal abnormalities and their relationship to the origin of the melasma. J Clin Endocrinol Metab 61:28–31PubMedCrossRefGoogle Scholar
  8. 8.
    Grimes PE, Yamada N, Bhawan J (2005) Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am J Dermatopathol 27:96–101PubMedCrossRefGoogle Scholar
  9. 9.
    Torres-Alvarez B, Mesa-Garza IG, Castanedo-Cazares JP et al (2011) Histochemical and immunohistochemical study in melasma: evidence of damage in the basal membrane. Am J Dermatopathol 33:291–295PubMedCrossRefGoogle Scholar
  10. 10.
    Resnik S (1967) Melasma induced by oral contraceptive drugs. JAMA 199:601–605PubMedCrossRefGoogle Scholar
  11. 11.
    Lakhdar H, Zouhair K, Khadir K et al (2007) Evaluation of the effectiveness of a broad-spectrum sunscreen in the prevention of chloasma in pregnant women. J Eur Acad Dermatol Venereol 21:738–742PubMedCrossRefGoogle Scholar
  12. 12.
    Rajaratnam R, Halpern J, Salim A et al. (2010) Interventions for melasma. Cochrane Database Syst Rev CD003583Google Scholar
  13. 13.
    Mauricio T, Karmon Y, Khaiat A (2011) A randomized and placebo-controlled study to compare the skin-lightening efficacy and safety of lignin peroxidase cream vs. 2% hydroquinone cream. J Cosmet Dermatol 10:253–259PubMedCrossRefGoogle Scholar
  14. 14.
    Draelos ZD (2007) Skin lightening preparations and the hydroquinone controversy. Dermatol Ther 20:308–313PubMedCrossRefGoogle Scholar
  15. 15.
    Levitt J (2007) The safety of hydroquinone: a dermatologist’s response to the 2006 Federal Register. J Am Acad Dermatol 57:854–872PubMedCrossRefGoogle Scholar
  16. 16.
    Bentley-Phillips B, Bayles MA (1975) Cutaneous reactions to topical application of hydroquinone. Results of a 6-year investigation. S Afr Med J 49:1391–1395PubMedGoogle Scholar
  17. 17.
    Berson DS, Cohen JL, Rendon MI et al (2009) Clinical role and application of superficial chemical peels in today’s practice. J Drugs Dermatol 8:803–811PubMedGoogle Scholar
  18. 18.
    Jang WS, Lee CK, Kim BJ et al (2011) Efficacy of 694-nm Q-switched ruby fractional laser treatment of melasma in female Korean patients. Dermatol Surg 37:1133–1140PubMedCrossRefGoogle Scholar
  19. 19.
    Zhou X, Gold MH, Lu Z et al (2011) Efficacy and safety of Q-switched 1,064-nm neodymium-doped yttrium aluminum garnet laser treatment of melasma. Dermatol Surg 37:962–970PubMedCrossRefGoogle Scholar
  20. 20.
    Barysch MJ, Rummelein B, Kolm I et al (2012) Split-face study of melasma patients treated with non-ablative fractionated photothermolysis (1540 nm). J Eur Acad Dermatol Venereol 26:423–430PubMedCrossRefGoogle Scholar
  21. 21.
    Karsai S, Fischer T, Pohl L et al (2012) Is non-ablative 1550-nm fractional photothermolysis an effective modality to treat melasma? Results from a prospective controlled single-blinded trial in 51 patients. J Eur Acad Dermatol Venereol 26:470–476PubMedCrossRefGoogle Scholar
  22. 22.
    Kroon MW, Wind BS, Beek JF et al (2011) Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot study. J Am Acad Dermatol 64:516–523PubMedCrossRefGoogle Scholar
  23. 23.
    Wind BS, Kroon MW, Meesters AA et al (2010) Non-ablative 1,550 nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled split-face study. Lasers Surg Med 42:607–612PubMedCrossRefGoogle Scholar
  24. 24.
    Trelles MA, Velez M, Gold MH (2010) The treatment of melasma with topical creams alone, CO2 fractional ablative resurfacing alone, or a combination of the two: a comparative study. J Drugs Dermatol 9:315–322PubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • Shlomit Halachmi
    • 1
  • Merete Haedersdal
    • 2
  • Moshe Lapidoth
    • 1
    • 3
  1. 1.Laser UnitRabin Medical CenterPetach TikvaIsrael
  2. 2.Department of Dermatology, Bispebjerg HospitalUniversity of CopenhagenCopenhagenDenmark
  3. 3.Sackler School of MedicineTel Aviv UniversityTel AvivIsrael

Personalised recommendations